Evidence map›Paper›PMID 37495851›Full record

ReviewHandbook of experimental pharmacology2024

Locus Coeruleus and Noradrenergic Pharmacology in Neurodegenerative Disease.

Rachel A Matt, Renee S Martin, Andrew K Evans, Joel R Gever, Gabriel A Vargas, Mehrdad Shamloo, Anthony P Ford

Abstract readReview
PubMed Publisher
In one paragraph

Review in Handbook of experimental pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Functional characterization of the αFrontiers in pharmacology · 2025
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rachel A MattCuraSen Therapeutics Inc., San Carlos, CA, USA. matt@curasen.com.ORCID https://orcid.org/0000-0002-9944-8897
Renee S MartinCuraSen Therapeutics Inc., San Carlos, CA, USA.ORCID https://orcid.org/0000-0002-3975-1480
Andrew K EvansDepartment of Neurosurgery, Stanford University School of Medicine, Palo Alto, CA, USA.ORCID https://orcid.org/0000-0003-2986-6476
Joel R GeverCuraSen Therapeutics Inc., San Carlos, CA, USA.ORCID https://orcid.org/0000-0001-9968-2299
Gabriel A VargasCuraSen Therapeutics Inc., San Carlos, CA, USA.ORCID https://orcid.org/0000-0001-8511-6042
Mehrdad ShamlooDepartment of Neurosurgery, Stanford University School of Medicine, Palo Alto, CA, USA.ORCID https://orcid.org/0000-0003-4404-1755
Anthony P FordCuraSen Therapeutics Inc., San Carlos, CA, USA.ORCID https://orcid.org/0000-0001-8618-0273
Stanford University · USExicure (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adrenoceptors (ARs) throughout the brain are stimulated by noradrenaline originating mostly from neurons of the locus coeruleus, a brainstem nucleus that is ostensibly the earliest to show detectable pathology in neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. The α

Indexed as

Locus CoeruleusNeurodegenerative DiseasesNorepinephrineAnimalsCognitionHumansReceptors, AdrenergicNorepinephrineReceptors, AdrenergicAdrenergic reuptake inhibitorsAerobic glycolysisAlpha adrenergic receptorAlpha-synucleinopathiesAlzheimer’s diseaseBeta adrenergic receptorCerebral blood flowDementiaG protein-coupled receptorsLocus coeruleusNeurodegenerative disordersNeuroinflammationNeurovascular couplingNoradrenalineNorepinephrineParkinson’s diseaseTauopathy

Identifiers

PMID37495851
OpenAlexW4385266278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.